Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice

Neurochemistry International

Volumn 57, Issue 5, 2010, Pages 489-491

  Khan, Haseeb Ahmad ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidant; Dopamine; Inflammation; MPTP; Parkinson disease; Selenium

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; SODIUM CHLORIDE; SODIUM SELENITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DOPAMINE; HOMOVANILLIC ACID; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; SELENIUM COMPOUNDS;

ANIMALIA; MUS;

EID: 77956226633     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.06.020     Document Type: Article

References (25)

1. Bahat-Stroomza M., Gilgun-Sherki Y., Offen D., et al. A novel thiol antioxidant that crosses the blood-brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur. J. Neurosci. 2005, 21:637-646.
2. Ballard P.A., Tetrud J.W., Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949-956.
3. Battin E.E., Perron N.R., Brumaghim J.L. The central role of metal coordination in selenium antioxidant activity. Inorg. Chem. 2006, 45:499-501.
4. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr. Neurosci. 2002, 5:363-374.
5. Beyrouty P., Chan H.M. Co-consumption of selenium and vitamin E altered the reproductive and developmental toxicity of methylmercury in rats. Neurotoxicol. Teratol. 2006, 28:49-58.
6. Cadet J.L. The potential use of vitamin E and selenium in parkinsonism. Med. Hypotheses. 1986, 20:87-94.
7. Chiueh C.C., Wu R.M., Mohankumar K.P., et al. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N.Y. Acad. Sci. 1994, 738:25-36.
8. Imam S.Z., Newport G.D., Islam F., Slikker W., Ali S.F. Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity. Brain Res. 1999, 818:575-578.
9. Johannsen P., Velander G., Mai J., Thorling E.B., Dupont E. Glutathione peroxidase in early and advanced Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1991, 54:679-682.
10. Khan H.A. Time course evaluation of whole blood phagocytosis in mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Inflammopharmacology 2004, 12:81-88.
11. Kim H., Jhoo W., Shin E., Bing G. Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Res. 2000, 862:247-252.
12. Kurkowska-Jastrzebska I., Litwin T., Noniec I., et al. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 2004, 4:1307-1318.
13. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 1999, 59:1-8.
14. Li X.J., Gu J., Lu S.D., Sun F.Y. Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. J. Pineal Res. 2002, 32:47-52.
15. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009, 89:277-287.
16. Mandel S., Grunblatt E., Maor G., Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem. Res. 2002, 27:1231-1243.
17. Oztas B., Kilic S., Dural E., Ispir T. Influence of antioxidants on the blood-brain barrier permeability during epileptic seizures. J. Neurosci. Res. 2001, 66:674-678.
18. Park S.W., Kim S.H., Park K.H., et al. Preventive effects of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci. Lett. 2004, 363:243-246.
19. Pfeiffer R.F. Neuroinflammation and Parkinson disease: the silent battleground. Neurology 2009, 73:1434-1435.
20. Roberts M.E. Antiinflammation studies II. Antiinflammatory properties of selenium. Toxicol. Appl. Pharmacol. 1963, 5:500-506.
21. Santamaria A., Salvatierra Sanchez R., Vazquez Roman B., et al. Protective effects of the antioxidant selenium on quinolinic acid induced neurotoxicity in rats: in vitro and in vivo studies. J. Neurochem. 2003, 86:479-488.
22. Sutphin M.S., Buckman T.D. Effects of low selenium diets on antioxidant status and MPTP toxicity in mice. Neurochem. Res. 1991, 16:1257-1263.
23. Tariq M., Khan H.A., Al Moutaery K., Al Deeb S. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of parkinsonism in rodents. Brain Res. Bull. 2001, 54:77-82.
24. Tsunoda M., Johnson V.J., Sharma R.P. Increase in dopamine metabolites in murine striatum after oral exposure to inorganic but not organic form of selenium. Arch. Environ. Contam. Toxicol. 2000, 39:32-37.
25. Vizuete M.L., Steffen V., Machado A., Cano J. 1-Methyl-4-phenylpyridinium has greater neurotoxic effect after selenium deficiency than after vitamin E deficiency in rat striatum. Eur. J. Pharmacol. 1994, 270:183-187.